Amgen Inc. (NASDAQ:AMGN) had its target price raised by equities researchers at UBS AG from $175.00 to $185.00 in a note issued to investors on Wednesday, www.benzinga.com reports. The firm currently has a “neutral” rating on the medical research company’s stock. UBS AG’s price objective points to a potential upside of 5.18% from the company’s previous close.

Other analysts have also issued research reports about the company. Deutsche Bank AG assumed coverage on Amgen in a research note on Friday, June 23rd. They set a “hold” rating and a $172.00 price objective on the stock. Credit Suisse Group restated a “hold” rating and issued a $178.00 price objective on shares of Amgen in a report on Tuesday, April 4th. ValuEngine downgraded Amgen from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Oppenheimer Holdings, Inc. set a $189.00 price objective on Amgen and gave the stock a “buy” rating in a report on Monday, June 5th. Finally, Mizuho restated a “buy” rating and issued a $195.00 price objective on shares of Amgen in a report on Monday, April 3rd. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating, eleven have issued a buy rating and three have issued a strong buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $187.03.

Shares of Amgen (NASDAQ AMGN) traded down 2.76% during midday trading on Wednesday, hitting $175.89. 5,445,635 shares of the stock were exchanged. The firm has a 50 day moving average of $170.78 and a 200-day moving average of $165.90. Amgen has a one year low of $133.64 and a one year high of $184.21. The company has a market cap of $129.35 billion, a price-to-earnings ratio of 16.71 and a beta of 1.36.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.11 by $0.16. The company had revenue of $5.81 billion for the quarter, compared to analyst estimates of $5.67 billion. Amgen had a return on equity of 29.37% and a net margin of 34.42%. Amgen’s revenue was up 2.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.84 earnings per share. Equities analysts expect that Amgen will post $12.48 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Amgen Inc. (NASDAQ:AMGN) Given New $185.00 Price Target at UBS AG” was posted by American Banking News and is the property of of American Banking News. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/07/26/amgen-inc-nasdaqamgn-given-new-185-00-price-target-at-ubs-ag.html.

In other Amgen news, SVP Cynthia M. Patton sold 2,922 shares of the stock in a transaction dated Wednesday, May 24th. The stock was sold at an average price of $154.40, for a total transaction of $451,156.80. Following the completion of the transaction, the senior vice president now owns 24,214 shares in the company, valued at approximately $3,738,641.60. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 0.20% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently added to or reduced their stakes in the company. TrimTabs Asset Management LLC boosted its position in Amgen by 88.9% in the first quarter. TrimTabs Asset Management LLC now owns 612 shares of the medical research company’s stock worth $100,000 after buying an additional 288 shares during the period. Thomas J. Herzfeld Advisors Inc. purchased a new position in Amgen during the fourth quarter worth about $102,000. Alpha Omega Wealth Management LLC boosted its position in Amgen by 19.0% in the first quarter. Alpha Omega Wealth Management LLC now owns 625 shares of the medical research company’s stock worth $103,000 after buying an additional 100 shares during the period. Jackson Grant Investment Advisers Inc. boosted its position in Amgen by 0.6% in the first quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock worth $104,000 after buying an additional 4 shares during the period. Finally, American Beacon Advisors Inc. purchased a new position in Amgen during the first quarter worth about $106,000. Hedge funds and other institutional investors own 78.87% of the company’s stock.

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Analyst Recommendations for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.